Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed
NCT ID: NCT05592756
Last Updated: 2023-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2964 participants
OBSERVATIONAL
2020-04-06
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The proposed study will involve the collection and analysis of contact data from measles cases oriented to compare vaccinated and unvaccinated, differing from health surveillance actions. This is based on an exhaustive search for contacts of measles cases, preferably aimed at detecting susceptible individuals, with the purpose of implementing blocking vaccination and interrupting the transmission chain.
The proposed study seeks a representation of contacts, without the intention of being exhaustive in the search and detection, but prioritizing selection without bias for one of the exposure groups (vaccination).
The results may provide technical and scientific support for future decisions by the Ministry of Health regarding the primary immunization schedule, the priority of the age group in vaccination campaigns, the identification of susceptible individuals, and the assessment of the need for a 3rd dose of the vaccine, for measles.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)
NCT05154097
Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?
NCT04445610
Measles, Mumps, and Rubella (MMR) Immunity in College Students
NCT00962819
A Second Dose of Measles Vaccine (MV) in the Second Year of Life
NCT02943681
Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings
NCT06667206
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* Willingness to answer the study questionnaire.
* Have had contact with the index case, 6 days before the appearance of the rash, up to 18 days after.
* Have proof of vaccination (or authorize access to health unit vaccination records) or if you no longer have a vaccination card, state whether you have had a vaccine in the past or not.
* Willingness to provide name, address, telephone and other information so that the principal investigator and his team can contact you, if necessary (example: in case of missed visit).
* Willingness to strictly follow the study protocol.
* At least one of the legal guardians for the research participants must be able to understand and sign the Free and Informed Consent Form. If those responsible are unable to sign (illiterate), the IC can be signed by an impartial witness who has accompanied the entire procedure
* For those over 6 years old, and under 18 years old, ability to understand and sign the Informed Consent Form.
* For those over 18, ability to understand and sign the Informed Consent Form.
Exclusion Criteria
* Inform that you do not know the vaccination status.
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eliane Matos dos Santos
Rio de Janeiro, , Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASCLIN 003/2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.